Drug intelligence / Profile preview

albuterol

Development stage: Preclinical
Lead developer: DMK Pharmaceuticals
Modality: Small Molecules
Administration: Inhalation

Overview

APC-2000 is a dry powder inhaler (DPI) formulation of albuterol, a short-acting beta-2 adrenergic agonist (SABA), developed by Adamis Pharmaceuticals. It is intended for the treatment and prevention of bronchospasm in patients with asthma or chronic obstructive pulmonary disease (COPD). As a bronchodilator, albuterol works by selectively binding to and activating beta-2 adrenergic receptors in the lungs, which leads to the relaxation of bronchial smooth muscle and subsequent dilation of the airways. APC-2000 was designed to provide a portable, breath-actuated delivery system as an alternative to traditional pressurized metered-dose inhalers (pMDIs), utilizing Adamis's proprietary inhaler technology.

Other names: albuterol dry powder inhalersalbutamol

Targets

ADRB1 (β1)

Beyond the preview

Go deeper on albuterol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on albuterol.

Explore the full profile